ArticleScientific reports2025
USP15-dependent modulation of TGF-β/Smad2/3 signaling: implications for chondrocyte matrix degradation and autophagy in osteoarthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The dysregulation of extracellular matrix (ECM) metabolism and autophagy in chondrocytes is central to osteoarthritis (OA) pathogenesis, yet the molecular mechanisms remain poorly defined. Ubiquitin-specific protease 15 (USP15), a key modulator of TGF-β/Smad2/3 signaling through TβR-I stabilization, may play a critical role in maintaining chondrocyte homeostasis. We conducted in vitro and ex vivo experiments using OA patient-derived cartilage samples and chondrocyte models to test the hypotheses that (1) USP15 deficiency exacerbates OA progression by impairing TGF-β/Smad2/3 signaling, leading to ECM degradation and autophagy dysfunction; and (2) restoring USP15 expression activates this pathway to mitigate cartilage degeneration, an effect reversible by TGF-β/Smad inhibition. Lentiviral-mediated USP15 knockdown or overexpression, combined with pharmacological inhibition assays, revealed that reduced USP15 levels in OA lesions correlated with disease severity (Kellgren-Lawrence grading) and triggered ECM catabolism (downregulated Col-II, MMP-13), suppressed autophagy (reduced LC3-II, accumulated p62), and increased apoptosis. Conversely, USP15 overexpression stabilized TβR-I, enhanced TGF-β/Smad2/3 signaling activity, increased Smad2/3 protein expression and promoted Smad2/3 phosphorylation(p < 0.01), and restored ECM synthesis and autophagic flux. These protective effects were abolished by the TGF-β receptor kinase inhibitor SIS3 (p < 0.001), confirming pathway dependency. Our findings establish USP15 as a pivotal regulator of chondrocyte homeostasis via the TβR-I/Smad axis, offering novel therapeutic targets for OA intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.